heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-28 and is reviewed periodically as new material appears.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue with a C-terminal Pro-Gly-Pro tail |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Abbreviated TKPRPGP in most catalogues |
| Molecular mass | About 752 Da | Value for the free peptide |
| Solubility | Freely soluble in water | Aqueous solutions are kept cold and used promptly |
| Typical storage | -20 °C, dry, protected from light | Applies to the lyophilised powder before reconstitution |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Organ on a chip applications: For example organoids can be used to model diseases with cells derived from patients or they can be used to investigate the development of different tissues (for example the nervous system) in humans and other animals. Some of these areas are further elaborated in the sections below:
Xi's position as the apparent successor to become the paramount leader was threatened with the rapid rise of Bo Xilai, the party secretary of Chongqing at the time. Bo was expected to join the PSC after the 18th Party Congress, with most expecting that he would try to eventually maneuver himself into replacing Xi. Bo's policies in Chongqing inspired imitations throughout China and received praise from Xi himself during Xi's visit to Chongqing in 2010. Records of praises from Xi were later erased after he became paramount leader. Bo's downfall would come with the Wang Lijun incident, which opened the door for Xi to come to power without challengers. On 18 October 2010, at the fifth plenary session of the 17th Central Committee, Xi was elected to be a vice chairman of the CCP Central Military Commission, followed by his appointment as vice chairman of the state CMC on 28 October by the Standing Committee of the National People's Congress. A few months before his ascendancy to the party leadership, Xi disappeared from official media coverage and cancelled meetings with foreign officials for several weeks beginning on 1 September 2012, causing rumors. He then reappeared on 15 September. On 15 November 2012, immediately after the 18th Party National Congress, Xi was elected by the first plenary session the 18th Central Committee to the posts of Party general secretary and chairman of the Party CMC. This made him both the CCP leader and, informally, China's paramount leader. The following day Xi led the new line-up of the PSC onto the stage in their first public appearance.
== Academic and professional activities == Throughout 37 years of activity, Mendes published some 150 articles, During this time, he created various inventions and innovations in the field of Implant Surgery, Bio materials, Orthopedic instruments and surgical techniques. As a result, he is the owner of several international patents. Mendes introduced the Total Knee Arthroplasty operation for the first time in Israel, a technology he studied in the USA. By combining materials developed in Germany and France, he was able to extend the service life of the implant. As part of his activities in the Center for Implant Surgery, Mendes created a platform for cooperation with researchers from the Technion, the Hebrew University and the high tech industry. These efforts were directed at the investigation of influence of different types of energy on bone restructure and fracture healing, development of new implants and replacement parts for joints and ligaments and contributed to the arising field of Computed Tomography. Together with International teams financed by the German-Israel Foundation, Mendes managed several research efforts into the replacement of ligaments with synthetic fibers and the design of artificial replacement of the bony patella.
Sources: en.wikipedia.org
Proteins of the Proton-dependent Oligopeptide Transporter (POT) Family (also called the PTR (peptide transport) family) are found in animals, plants, yeast, archaea and both Gram-negative and Gram-positive bacteria, and are part of the major facilitator superfamily. The transport of peptides into cells is a well-documented biological phenomenon which is accomplished by specific, energy-dependent transporters found in a number of organisms as diverse as bacteria and humans. The proton-dependent oligopeptide transporter (PTR) family of proteins is distinct from the ABC-type peptide transporters and was uncovered by sequence analyses of a number of recently discovered peptide transport proteins. These proteins that seem to be mainly involved in the intake of small peptides with the concomitant uptake of a proton.
=== United Kingdom === Beak trimming is legal but regulated in the UK; it is expected that the practice will be prohibited in the near future. In 2011, the British government set up the Beak Trimming Action Group (BTAG) to review the matter with representatives from different stakeholders, including the industry, the government, animal welfare groups and veterinarians. A late 2015 BTAG report endorsed by Farming Minister George Eustice concluded that banning it in January 2016 would be too early as the sector needed more time to change its management techniques in order to avoid feather pecking, but that beak trimming should be phased out in the future. Laying Hen Welfare Forum chairman Andrew Joret stated in March 2020: 'A ban is coming. In my opinion, we have five years at most to prepare for this. We need to work out ways of keeping birds well-feathered, and if we can, eventually do that without beak trimming.'
=== Employee insider trading scandal === On the evening of September 29, 2016, Hanmi announced the Roche deal, causing its stock to rise; Hanmi was notified by Boehringer that evening that Boehringer was terminating their deal, and the company announced the termination on the morning of the 30th, causing its stock to crash. Hanmi's offices were raided by Korean regulatory authorities in mid-October based on evidence that insider knowledge of the Boehringer termination was passed to third parties, who shorted the stock prior to the announcement on the 30th. In December three Hanmi employees were among 17 people indicted for insider trading; 25 people were fined, and 45 people were found to have made illegal trades that took around 3.3 billion won ($2.83 million) in profits based on the information.
Sources: en.wikipedia.org
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.
Tuftsin is a natural tetrapeptide derived from the Fc portion of immunoglobulin G. Selank retains that tetrapeptide at its N-terminus and adds three residues to improve resistance to enzymatic breakdown. The relationship is structural, and the two molecules are not interchangeable in experimental work.
It holds a product registration in Russia for intranasal use as an anxiolytic. Registrations of that kind are not automatically accepted by regulators elsewhere. In most other countries it is treated as an unapproved substance or a research material.
Selank is a synthetic peptide made of seven amino acids. It is modeled on tuftsin, a natural tetrapeptide, with an added three-residue tail. It is not a small-molecule drug.